Small-Molecule inhibitors of usp1 target id1 degradation in leukemic cells

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2651-2662

  Mistry, Helena ^a   Hsieh, Grace ^a   Buhrlage, Sara J ^b   Huang, Min ^a   Park, Eunmi ^a   Cuny, Gregory D ^c   Galinsky, Ilene ^a   Stone, Richard M ^a   Gray, Nathanael S ^b   D'Andrea, Alan D ^a   Parmar, Kalindi ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Departments of Systems Biology   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; RHODAMINE; UBIQUITIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HOMOLOGOUS RECOMBINATION; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARABIDOPSIS PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HIGH-THROUGHPUT SCREENING ASSAYS; HOMOLOGOUS RECOMBINATION; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITORY CONCENTRATION 50; LEUKEMIA; MICE; PIMOZIDE; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEOLYSIS; UBIQUITIN-SPECIFIC PROTEASES; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890525480     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0103-T     Document Type: Article

References (50)

1. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001;20:8326-33
2. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell1990;61:49-59
3. Langlands K, Yin X, Anand G, Prochownik EV. Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. J Biol Chem 1997;272:19785-93
4. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation,and tumorigenesis. J Cell Sci 2000;113:3897-905
5. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, et al.Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999;155:815-22
6. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B,Birner P. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res 2001;61:5703-6
7. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, Horvat R,et al. Level of Id-1 protein expression correlates with poor differentiation,enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 2003;9:779-85
8. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol 2002;167:2598-602
9. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, et al. Arole for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 2000;60:1332-40
10. O'Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L,WangY, et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancerinitiating cells through p21. Cancer Cell 2012;21:777-92
11. Soroceanu L, Murase R, Limbad C, Singer EL, Allison J, Adrados I, et al.Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 2013;73:1559-69
12. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004;25:881-7
13. Hu H, Han HY, Wang YL, Zhang XP, Chua CW, Wong YC, et al. The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells. Oncol Rep 2009;21:1053-9
14. Fong S, Debs RJ, Desprez PY. Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 2004;10:387-92
15. Yokota Y, Mori S. Role of Id family proteins in growth control. J Cell Physiol 2002;190:21-8
16. Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, et al. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood 2009;114:2993-3000.
17. Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Frohling S, et al. Id1 is a common downstreamtarget of oncogenic tyrosine kinases in leukemic cells. Blood 2008;112:1981-92
18. Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, Renn K, Gooya J, et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 2008;27: 5612-23
19. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005;5:603-14
20. Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB, et al. USP1 eubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 2011;146:918-30
21. Lasorella A, Stegmuller J, Guardavaccaro D, Liu G, Carro MS, Rothschild G, et al. Degradation of Id2 by the anaphase-promoting complex couples cell-cycle exit and axonal growth. Nature 2006;442:471-4
22. Bounpheng MA, Dimas JJ, Dodds SG, Christy BA. Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB J 1999; 13:2257-64
23. Kong Y, Cui H, Zhang H. Smurf2-mediated ubiquitination and degradation of Id1 regulates p16 expression during senescence. Aging Cell 2011;10:1038-46
24. Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, et al. A UAF1- containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell 2007;28:786-97
25. Mermerian AH, Case A, Stein RL, Cuny GD. Structure-activity relationship, inetic echanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett 2007;17:3729-32
26. Cohn MA, Kee Y, Haas W, Gygi SP, D'Andrea AD. UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem 2009; 284:5343-51
27. Kee Y, Yang K, Cohn MA, Haas W, Gygi SP, D'Andrea AD. WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. J Biol Chem 2010;285:11252-7.
28. Vinciguerra P, Godinho SA, Parmar K, Pellman D, D'Andrea AD. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J Clin Invest 2010; 120:3834-42
29. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8
30. Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD. The FANCM/FAAP24 complex is required for the DNA interstrand crosslink- induced checkpoint response. Mol Cell 010;39:259-68
31. Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006;8:339-47
32. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL, et al. Chemistry- based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol 2002;9: 1149-59
33. Piatkov KI, Colnaghi L, Bekes M, Varshavsky A, Huang TT. The autogenerated fragment of the usp1 deubiquitylase is a physiological substrate of the N-end rule pathway. Mol Cell 2012;48:926-33
34. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol 2011;18:1390-400
35. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011;117:3421-9
36. Huang TT, D'Andrea AD. Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006;7:323-34
37. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005;17:331-9
38. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
39. Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012;26:1393-408
40. Oestergaard VH, Langevin F, Kuiken HJ, Pace P, Niedzwiedz W, Simpson LJ, et al. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell 2007;28:798-809
41. Kim JM, Parmar K, Huang M, Weinstock DM, Ruit CA, Kutok JL, et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 2009;16:314-20
42. Ruzinova MB, Benezra R. Id proteins in development, cell cycle, and cancer. Trends Cell Biol 2003;13:410-8.
43. Nam HS, Benezra R. High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell 2009;5:515-26.
44. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF-beta receptor inhibitors target the CD44(high)/ Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010;18:655-68.
45. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 utations. Genes Cancer 2012;3:503-11
46. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-7
47. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, et al. Id-1 as a molecular target in herapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2003;100:13543-8
48. Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, Wasik MA, et al. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res 2006;66: 4108- 16
49. Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, et al. Peptideconjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 008;26:91-100
50. Mern DS, Hasskarl J, Burwinkel B. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer 2010;103:1237-44. Mistry et al